PortalPublikationenThe impact of HER2 phenotype of circulating tumor cells in m...

The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients

Standard

The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients. / Wallwiener, Markus; Hartkopf, Andreas Daniel; Riethdorf, Sabine; Nees, Juliane; Sprick, Martin Ronald; Schönfisch, Birgitt; Taran, Florin-Andrei; Heil, Jörg; Sohn, Christof; Pantel, Klaus; Trumpp, Andreas; Schneeweiss, Andreas.

in: BMC CANCER, Jahrgang 15, 14.05.2015, S. Art. 403.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Wallwiener, M, Hartkopf, AD, Riethdorf, S, Nees, J, Sprick, MR, Schönfisch, B, Taran, F-A, Heil, J, Sohn, C, Pantel, K, Trumpp, A & Schneeweiss, A 2015, 'The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients', BMC CANCER, Jg. 15, S. Art. 403. https://doi.org/10.1186/s12885-015-1423-6

APA

Wallwiener, M., Hartkopf, A. D., Riethdorf, S., Nees, J., Sprick, M. R., Schönfisch, B., Taran, F-A., Heil, J., Sohn, C., Pantel, K., Trumpp, A., & Schneeweiss, A. (2015). The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients. BMC CANCER, 15, Art. 403. https://doi.org/10.1186/s12885-015-1423-6

Vancouver

Wallwiener M, Hartkopf AD, Riethdorf S, Nees J, Sprick MR, Schönfisch B et al. The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients. BMC CANCER. 2015 Mai 14;15:Art. 403. https://doi.org/10.1186/s12885-015-1423-6

Bibtex

@article{ec0153ba3cf54fe5b9ac844168dbafd6,
title = "The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients",
abstract = "BACKGROUND: In metastatic breast cancer (MBC), antigen profiles of metastatic tissue and primary tumor differ in up to 20 % of patients. Reassessment of predictive markers, including human epidermal growth factor receptor 2 (HER2) expression, might help to optimize MBC treatment. While tissue sampling is invasive and often difficult to repeat, circulating tumor cell (CTC) analysis requires only a blood sample and might provide an easy-to-repeat, real-time {"}liquid biopsy{"} approach. The present retrospective study was conducted to compare HER2 expression in primary tumors, metastatic tissue, and circulating tumor cells (CTCs) from MBC patients and to analyze the potential impact of HER2 overexpression by CTCs on progression-free (PFS) and overall survival (OS) in MBC.METHODS: CTC-positive (five or more CTCs/7.5 mL blood; CellSearch{\textregistered}, Janssen Diagnostics) MBC patients starting a new line of systemic treatment were eligible for the study. HER2 status of CTCs was determined by immunofluorescence (CellSearch{\textregistered}). HER2 status of primary (PRIM) and metastatic (MET) tumor tissue was determined by immunohistochemistry. Data were analyzed using descriptive statistics and Kaplan-Meier plots.RESULTS: One hundred seven patients (median age (range) 57 (33-81) years) were included. 100/107 (93%) patients were followed-up for a median [95% confidence interval (CI)] of 28.5 [25.1-40.1] months. Of 37/107 (35%) CTC-HER2-positive patients only 10 (27%) were PRIM-HER2-positive. 6/46 (13%) patients were MET-HER2-positive; only 2/10 (20%) CTC-HER2-positive patients were MET-HER2-positive. Overall accuracy between CTC-HER2 expression and PRIM-HER2 and MET-HER2 status was 69% and 74%, respectively. Kaplan-Meier plots of PFS and OS by CTC-HER2 status revealed significantly longer median [95% CI] PFS of CTC-HER2-positive versus CTC-HER2-negative patients (7.4 [4.7-13.7] versus 4.34 [3.5-5.9] months; p = 0.035). CTC-HER2-positive status showed no significant difference for OS (13.7 [7.7-30.0] versus 8.7 [5.9-15.3] months; p = 0.287).CONCLUSIONS: HER2 status can change during the course of breast cancer. CTC phenotyping may serve as an easy-to-perform {"}liquid biopsy{"} to reevaluate HER2 status and potentially guide treatment decisions. Further, prospective studies are needed.",
author = "Markus Wallwiener and Hartkopf, {Andreas Daniel} and Sabine Riethdorf and Juliane Nees and Sprick, {Martin Ronald} and Birgitt Sch{\"o}nfisch and Florin-Andrei Taran and J{\"o}rg Heil and Christof Sohn and Klaus Pantel and Andreas Trumpp and Andreas Schneeweiss",
year = "2015",
month = may,
day = "14",
doi = "10.1186/s12885-015-1423-6",
language = "English",
volume = "15",
pages = "Art. 403",
journal = "BMC CANCER",
issn = "1471-2407",
publisher = "BioMed Central Ltd.",

}

RIS

TY - JOUR

T1 - The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients

AU - Wallwiener, Markus

AU - Hartkopf, Andreas Daniel

AU - Riethdorf, Sabine

AU - Nees, Juliane

AU - Sprick, Martin Ronald

AU - Schönfisch, Birgitt

AU - Taran, Florin-Andrei

AU - Heil, Jörg

AU - Sohn, Christof

AU - Pantel, Klaus

AU - Trumpp, Andreas

AU - Schneeweiss, Andreas

PY - 2015/5/14

Y1 - 2015/5/14

N2 - BACKGROUND: In metastatic breast cancer (MBC), antigen profiles of metastatic tissue and primary tumor differ in up to 20 % of patients. Reassessment of predictive markers, including human epidermal growth factor receptor 2 (HER2) expression, might help to optimize MBC treatment. While tissue sampling is invasive and often difficult to repeat, circulating tumor cell (CTC) analysis requires only a blood sample and might provide an easy-to-repeat, real-time "liquid biopsy" approach. The present retrospective study was conducted to compare HER2 expression in primary tumors, metastatic tissue, and circulating tumor cells (CTCs) from MBC patients and to analyze the potential impact of HER2 overexpression by CTCs on progression-free (PFS) and overall survival (OS) in MBC.METHODS: CTC-positive (five or more CTCs/7.5 mL blood; CellSearch®, Janssen Diagnostics) MBC patients starting a new line of systemic treatment were eligible for the study. HER2 status of CTCs was determined by immunofluorescence (CellSearch®). HER2 status of primary (PRIM) and metastatic (MET) tumor tissue was determined by immunohistochemistry. Data were analyzed using descriptive statistics and Kaplan-Meier plots.RESULTS: One hundred seven patients (median age (range) 57 (33-81) years) were included. 100/107 (93%) patients were followed-up for a median [95% confidence interval (CI)] of 28.5 [25.1-40.1] months. Of 37/107 (35%) CTC-HER2-positive patients only 10 (27%) were PRIM-HER2-positive. 6/46 (13%) patients were MET-HER2-positive; only 2/10 (20%) CTC-HER2-positive patients were MET-HER2-positive. Overall accuracy between CTC-HER2 expression and PRIM-HER2 and MET-HER2 status was 69% and 74%, respectively. Kaplan-Meier plots of PFS and OS by CTC-HER2 status revealed significantly longer median [95% CI] PFS of CTC-HER2-positive versus CTC-HER2-negative patients (7.4 [4.7-13.7] versus 4.34 [3.5-5.9] months; p = 0.035). CTC-HER2-positive status showed no significant difference for OS (13.7 [7.7-30.0] versus 8.7 [5.9-15.3] months; p = 0.287).CONCLUSIONS: HER2 status can change during the course of breast cancer. CTC phenotyping may serve as an easy-to-perform "liquid biopsy" to reevaluate HER2 status and potentially guide treatment decisions. Further, prospective studies are needed.

AB - BACKGROUND: In metastatic breast cancer (MBC), antigen profiles of metastatic tissue and primary tumor differ in up to 20 % of patients. Reassessment of predictive markers, including human epidermal growth factor receptor 2 (HER2) expression, might help to optimize MBC treatment. While tissue sampling is invasive and often difficult to repeat, circulating tumor cell (CTC) analysis requires only a blood sample and might provide an easy-to-repeat, real-time "liquid biopsy" approach. The present retrospective study was conducted to compare HER2 expression in primary tumors, metastatic tissue, and circulating tumor cells (CTCs) from MBC patients and to analyze the potential impact of HER2 overexpression by CTCs on progression-free (PFS) and overall survival (OS) in MBC.METHODS: CTC-positive (five or more CTCs/7.5 mL blood; CellSearch®, Janssen Diagnostics) MBC patients starting a new line of systemic treatment were eligible for the study. HER2 status of CTCs was determined by immunofluorescence (CellSearch®). HER2 status of primary (PRIM) and metastatic (MET) tumor tissue was determined by immunohistochemistry. Data were analyzed using descriptive statistics and Kaplan-Meier plots.RESULTS: One hundred seven patients (median age (range) 57 (33-81) years) were included. 100/107 (93%) patients were followed-up for a median [95% confidence interval (CI)] of 28.5 [25.1-40.1] months. Of 37/107 (35%) CTC-HER2-positive patients only 10 (27%) were PRIM-HER2-positive. 6/46 (13%) patients were MET-HER2-positive; only 2/10 (20%) CTC-HER2-positive patients were MET-HER2-positive. Overall accuracy between CTC-HER2 expression and PRIM-HER2 and MET-HER2 status was 69% and 74%, respectively. Kaplan-Meier plots of PFS and OS by CTC-HER2 status revealed significantly longer median [95% CI] PFS of CTC-HER2-positive versus CTC-HER2-negative patients (7.4 [4.7-13.7] versus 4.34 [3.5-5.9] months; p = 0.035). CTC-HER2-positive status showed no significant difference for OS (13.7 [7.7-30.0] versus 8.7 [5.9-15.3] months; p = 0.287).CONCLUSIONS: HER2 status can change during the course of breast cancer. CTC phenotyping may serve as an easy-to-perform "liquid biopsy" to reevaluate HER2 status and potentially guide treatment decisions. Further, prospective studies are needed.

U2 - 10.1186/s12885-015-1423-6

DO - 10.1186/s12885-015-1423-6

M3 - SCORING: Journal article

C2 - 25972110

VL - 15

SP - Art. 403

JO - BMC CANCER

JF - BMC CANCER

SN - 1471-2407

ER -